GLP-1 Medicines and Low Blood Sugar: Warning Signs

If you take a GLP-1 medicine, a discussion about blood sugar should include the rest of your medication list. The Wegovy label warns that combining treatment with insulin or certain diabetes medicines can increase hypoglycemia risk, including severe episodes. Knowing what to watch for and having an individual response plan matters more than assuming a weight-management prescription makes this concern irrelevant.

Which warning signs need emergency help?

Low blood sugar can cause shaking, sweating, a pounding heartbeat, weakness or unclear thinking. Symptoms vary between people. Severe hypoglycemia is a medical emergency. Call 911 for a seizure, unconsciousness, inability to wake or markedly reduced alertness. Following MedlinePlus first-aid guidance, do not give food or drink to an unconscious person or someone who cannot safely swallow. Do not wait for a routine appointment or a reply to an online message when someone needs immediate help.

What does hypoglycemia mean?

Hypoglycemia means blood glucose has fallen below a healthy level. The NIDDK explanation of hypoglycemia  notes that, for many people with diabetes, this means below 70 mg/dL; individual thresholds can differ. Ask your care team what number requires action for you. Some people stop noticing early warning symptoms, particularly after repeated episodes. Feeling normal therefore cannot always establish that glucose is in range.

Why do insulin and sulfonylureas matter?

The current Wegovy prescribing information  identifies insulin and insulin-releasing medicines, such as sulfonylureas, as important combination risks. These are specific medicines, rather than every pill prescribed for diabetes. Bring the names of all prescriptions to the discussion, including medicines managed by another clinician.

The Zepbound hypoglycemia warning  similarly highlights insulin and sulfonylureas. Zepbound contains tirzepatide, which acts at both GIP and GLP-1 receptors. Its label calls for glucose monitoring in patients with diabetes before and during treatment. A prescriber may need to adjust other glucose-lowering treatment; that decision should come with clear instructions.

Can low blood sugar happen without diabetes?

The Zepbound label also reports hypoglycemia in adults without type 2 diabetes. That does not mean every person taking it will have an episode, but it rules out a blanket assurance that a person without diabetes has no risk. Tell a clinician about unexplained episodes rather than dismissing them because the medicine was prescribed for weight management.

What can an insulin-treatment trial tell us?

The original SURPASS-5 randomized trial  studied 475 adults with type 2 diabetes whose glucose was inadequately controlled with insulin glargine, with or without metformin. Over 40 weeks, researchers compared added tirzepatide with placebo. Low-glucose events occurred in both groups, and the trial included a defined glucose-monitoring and insulin-adjustment protocol.

This was a particular treatment setting. Its results cannot supply a personal risk estimate for someone without diabetes or using a different medicine combination. A research protocol also should not become a do-it-yourself medication plan.

Why doesn't A1C settle a suspected low?

An A1C result answers a different question from a glucose reading during symptoms. The NIDDK guide to the A1C test  explains that A1C reflects average glucose over roughly three months and does not show sudden, temporary decreases. A result within your target therefore does not rule out brief lows.

At follow-up, bring available glucose records alongside your A1C. Ask how your clinician will evaluate symptoms and readings together, rather than relying on the average alone.

What should your prescriber plan cover?

Changes in eating, activity or alcohol intake can matter for people taking glucose-lowering medicines. NIDDK also identifies illness and skipped or delayed meals as relevant to low glucose. Mention previous lows, episodes you did not feel, and any recent changes to your routine.

Before starting or changing treatment, ask: Do any of my current medicines raise my risk? What monitoring is appropriate? Which readings or symptoms require prompt contact? What is my written response plan, and should it include a prescribed rescue medicine? Who should I contact after hours? Have the plan explained in language you understand, including what a family member should know. Keep instructions from different prescribers consistent.

Do these warnings apply to every peptide product?

Wegovy and Zepbound are specific FDA-approved medicines. Their evidence does not establish the safety or effectiveness of unrelated experimental peptides.

The FDA's explanation of compounded medicines  states that compounded preparations are not FDA-approved and do not undergo the agency's premarket verification of safety, effectiveness or quality. A preparation marketed as compounded semaglutide or tirzepatide should not be described as the approved branded product. Ask exactly what is being proposed and which evidence applies to it.

Frequently asked questions

Does every GLP-1 prescription cause low blood sugar?

No. A warning describes a possible risk, rather than an outcome everyone will experience. For Wegovy, the label highlights increased risk with insulin or insulin-releasing medicines. Your complete treatment plan matters when discussing that warning.

Can an acceptable A1C rule out low episodes?

No. A1C is a longer-term average and can miss temporary drops. Tell your clinician about suspected episodes even when your latest result meets the agreed target, and bring any relevant glucose records.

Should I change insulin or another medicine myself?

Ask the prescriber for an individual medication and low-glucose response plan. Zepbound's warning recognizes that accompanying insulin or sulfonylurea treatment may need adjustment. It does not provide a universal change for every patient. Follow your clinician's specific instructions and seek urgent help when needed.

Can severe symptoms wait for a telehealth visit?

No. Seizures, unconsciousness, inability to wake or a major loss of alertness require emergency help. Call 911. A scheduled virtual consultation is not a substitute for emergency assessment.

Prepare for a California telehealth conversation

For California residents reviewing weight-management options, start with our medical weight-loss information. SoCal Testosterone Clinic currently provides California-only telehealth, with no in-person clinic appointments. You can request a California telehealth consultation  to discuss your goals and medication history. Bring your exact product names, diabetes treatment list and questions about prior symptoms. A consultation does not guarantee a prescription or a particular medicine's availability.